Analyst Insights

Roth Capital Reinstates Buy On BioLineRx, Sees 267% Upside

In a report released this morning, Roth Capital analyst Joseph Pantginis reinitiated coverage on BioLineRx Ltd. (BLRX) with a Buy rating and an $8.

Feltl Reiterates Buy On EzChip Following Acquisition Of Tilera

In a research note issued today, Feltl and Company analyst Jeffrey Schreiner reiterated a Strong Buy on EzChip Semiconductor Inc. (EZCH) with a …

Topeka Maintains Buy On Twitter As World Cup Skyrockets Usage

In a research note issued today, Topeka Capital analyst Victor Anthony maintained a Buy rating on Twitter Inc. (TWTR) with a price target …

H.C. Wainwright Reiterates Buy On Agenus Following Phase 2 Data From Prophage Vaccine

In a research note released Tuesday, H.C.

Roth Capital Maintains Buy On ANI Pharmaceutical Following The Acquistion of Lithobid

In a research note released Tuesday, Roth Capital analyst Scott Henry maintained a Buy rating on ANI Pharmaceuticals (ANIP) and raised his price target to $40.00 (from $38.

H.C. Wainwright Reiterates Buy On CTI Biopharma Following Completion Of Phase 3 Trial

In a research report released Tuesday, HC Wainwright analyst Reni Benjamin reiterated a Buy rating on CTI BioPharma Corp (CTIC) with a price target of $6.00 following the completion of …

Regeneron Remains A Strong Long Term Pick, Says Roth Capital Analyst

In a research note released Monday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals, Inc. (REGN) and a price target of $382.

Roth Capital Reiterates Buy On Palatin Technologies, Keeps $6 Price Target

In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Palatin Technologies Inc. (PTN) and a price target of $6.

Roth Capital Affirms Buy Rating On Durata Therapeutics, Raises PT To $28

In a research report released today, Roth Capital analyst Ed Arce raised his price target on Durata Therapeutics (DRTX) to $28 (from $24), while maintaining a Buy rating on the stock. The new price target …

Roth Capital Slightly Raises Price Target On Plantronics, Maintains Buy

In a research note issued today, Roth Capital analyst Dave King raised his price target on Plantronics, Inc. (PLT) from $52.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts